logo-loader
viewUber Technologies Inc

Uber rival Bolt sees London passenger numbers surge 400%

After launching in the capital in June this year, Bolt now has 30,000 registered drivers, challenging Uber's once-dominant presence in the city

Uber Technologies Inc - Uber rival Bolt sees London passenger numbers surge 400%

Estonian taxi app Bolt, a rival of Uber Technologies Inc (NYSE:UBER) has seen passenger numbers surge to 1.5mln in December, a 400% increase since September, following its London launch in June.

Bolt, which is trying to differentiate itself from other ride-hailing firms by only taking 15% commission from its drivers compared to around 30% by its rivals, also said it had around 30,000 of its cars in London and unveiled a new hub for its drivers in Chiswick.

READ: Uber competitor Ola to launch in London in coming weeks

Formerly known as Taxify, Bolt currently operates in 30 countries across Europe on Africa and is supported by some serious financial backers including German car giant Daimler, which led a US$175mln funding round last year that valued the company at US$1bn, granting it ‘unicorn’ status.

Bolt’s success is likely to cause more problems for Uber’s operation in the capital following last month’s decision by Transport for London (TfL) not to renew the group’s operating licence when its current one expires before the end of the year.

TfL said that it had identified “a pattern of failures” and that it did not have confidence that the firm had “a robust system for protecting passenger safety”. Uber is currently appealing the decision, during which time it will still be allowed to operate in the city.

London is Uber’s largest European market, however with surging competitors and legal troubles its dominance in the city appears to be under threat.

Bolt isn’t the only competitor parking its tanks on Uber’s lawn, with Indian firm Ola announcing at the end of November that had also begun registering drivers in London after being granted a 15-month licence by TfL.

Negative headlines could boost rivals and fray investor patience

“Uber has never been short of competitors and this remains one of the biggest challenges that faces the company – and therefore shareholders – in business where the barriers to entry seem to be relatively low and in a world where capital seemingly remains cheap and plentiful”, said Russ Mould, investment director at AJ Bell.

“If Uber continues to attract negative headlines, or fails to win licences, this potentially puts off customers or at least means they are more open to experimenting with rival operators… Uber must therefore focus on providing a better service and not just a cheaper one, as price alone will not be enough of a weapon with so many rivals around.”

Mould added that having already exited the Chinese and Russian markets, Uber may at some stage “have to focus at being really good in one area” and not engage in ‘land grabs’ for more customers, as continuing to haemorrhage money will likely fray nerves with its investors.

“Shareholders seem willing to subsidise passengers for now, and swallow the operating losses, but with the shares still a third below the IPO price there is a risk that their patience may start to give way if Uber continues to record heavy losses and burn cash even as passenger numbers grow”, he said.

Uber’s shares were down 0.9% at US$28.82 in early trading in New York on Thursday.

--Adds share price--

Quick facts: Uber Technologies Inc

Price: 30.43 USD

NYSE:UBER
Market: NYSE
Market Cap: $52.77 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Rakuten Medical receives conditional approval in Japan for head and neck...

Rakuten Medical, Inc VP of Global Regulatory Peggy Berry tells Proactive the California-based biotechnology group has received conditional early approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW). Berry says the privately-held group's lead drug ASP-1929, which aims to...

14 hours, 2 minutes ago

3 min read